QLS4131
As of the edition of 20 October 2026, QLS4131 is a drug known only by a code name: in active development; acts on GPRC5D and TNFRSF17.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Code name only
- Registered trials
- 4, 0 stopped early
- Disease areas
- Immune system; Cancer; Blood and lymph; Heart and blood vessels; Nutrition and metabolism; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 0 | 2 | 0 |
| Phase 2 | 2 | 0 | 2 | 0 |
| All trials | 4 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Qilu Pharmaceutical | Lead sponsor of trials | 2024 to now |